Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser combo may cut eye injection burden for vein blockage patients

NCT ID NCT04444492

Disease control Sponsor: University of Giessen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding targeted laser treatment to the standard ranibizumab injections can help people with macular edema (swelling) from a central retinal vein occlusion need fewer injections over time. About 88 adults with this condition will receive either injections alone or injections plus laser. The goal is to see if the combination leads to a longer treatment-free period and fewer total injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

88 people

The number who actually took part.

Started

Aug 2020

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of macular edema due to central retinal vein occlusion foveal thickness \> 250 μm (measured by OCT) * Age \> 18 years * Written informed consent of the patient * BCVA score in the study eye between 24 letters (20/320) and 78 letters (20/25) measured in ETDRS chart * History of CRVO no longer than 6 months * Presence of capillary non-perfusion in peripheral retina larger than 5 disc areas documented in ultra wide-field fluorescein angiography * Ability and willingness to attend all scheduled visits and assessments Exclusion Criteria: * CRVO with ischemic maculopathy defined as diameter of the foveolar avascular zone larger than 2 optic disc diameters * Macular edema due to another etiology than retinal vein occlusion (e.g. diabetic maculopathy, uveitis, age related macular degeneration, Irvine-Gass syndrome) * History of idiopathic central serous chorioretinopathy * Presence of vitreoretinal interface disease (e.g. vitreomacular traction, epiretinal membrane), either on clinical examination or in OCT * An eye that, in the investigator's opinion, would not benefit from resolution of macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense subfoveal hard exudates * Aphakia in the study eye * Scatter laser photocoagulation or macular photocoagulation in the study eye prior to study entry * Intraocular or periocular injection of steroids in the study eye prior to study entry * Previous use of an anti-VEGF drug in the study eye * Cataract surgery or any other intraocular surgery in the study eye within 3 months prior to study entry * Uncontrolled glaucoma (defined as intraocular pressure ≥ 30 mm Hg despite treatment with maximal anti-glaucoma medications) * History of stroke, myocardial infarction, transient ischemic attacks within 3 months prior to the study * Pregnancy (positive urine pregnancy test) or lactation * The presence of active malignancy, including lymphoproliferative disorders. * History of allergy to fluorescein or any component of the ranibizumab formulation * Active intraocular infection * Participation in another simultaneous interventional medical investigation or trial * Women with child bearing potency without effective contraception (i. e. implants, injectables, combined oral contraceptives, some IUDs or vasectomised partner) during the conduct of the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central retinal vein occlusion with macular edema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

central retinal vein occlusion with macular edema retinal vein occlusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central retinal vein occlusion with macular edema

Contacts and locations

Locations

  • Augen-OP-Zentrum Zschopau, Praxis für Augenheilkunde

    Zschopau, Germany

  • Augenzentrum am St. Franziskus-Hospital Münster

    Münster, 48145, Germany

  • Hannover MHH Universitätsklinik für Augenheilkunde

    Hanover, 30625, Germany

  • Klinikum der Stadt Ludwigshafen Augenklinik

    Ludwigshafen, 67063, Germany

  • Ludwig-Maximilians-Universität München, Augenklinik

    München, Germany

  • Medizinische Universität Innsbruck, Klinik für Augenheilkunde und Optometrie

    Innsbruck, 6020, Austria

  • University Hospital of Leipzig Department of Ophthalmology

    Leipzig, 04103, Germany

  • Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg Klinik für Augenheilkunde

    Marburg, 35043, Germany

  • Universitätsklinikum Gießen, Klinik und Poliklinik für Augenheilkunde

    Giessen, Germany

  • Universitätsklinikum Klinik für Augenheilkunde Freiburg

    Freiburg im Breisgau, 79106, Germany

  • Universitätsklinikum Tübingen, Department für Augenheilkunde

    Tübingen, Germany

  • Universitätsklinikum Ulm, Klinik für Augenheilkunde

    Ulm, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.